AKTX (Akari Therapeutics) Institutional Ownership: 3.79% (As of Aug. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AKTX Akari Therapeutics PLC AKTX
32 GF Score
Price $7.99
View Full Analysis

What is Akari Therapeutics Institutional Ownership?

Akari Therapeutics AKTX +7.71% 32 Institutional Ownership is 3.79% as of Aug. 16, 2026. GuruFocus rates AKTX with a GF Score™ of 32/100.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Akari Therapeutics's institutional ownership is 3.79%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Akari Therapeutics's Insider Ownership is 0.88%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Akari Therapeutics's Float Percentage Of Total Shares Outstanding is 52.56%.

Akari Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Akari Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akari Therapeutics Institutional Ownership Chart

Akari Therapeutics Historical Data

The historical data trend for Akari Therapeutics can be seen below:

2025-05-31 2025-06-30 2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28
Institutional Ownership 0.04 0.04 0.04 0.04 0.04 0.03 0.03 0.03 0.03 0.03
AKTX
32GF Score
Akari Therapeutics PLC AKTX
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akari Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 3.79% mean?
Akari Therapeutics (AKTX) has a Institutional Ownership of 3.79% as of Aug. 16, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Akari Therapeutics and its competitors.
Is Akari Therapeutics' Institutional Ownership too high?
Akari Therapeutics' current Institutional Ownership is 3.79%. Overall, Akari Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Akari Therapeutics' Institutional Ownership compare to MBRX and INTI?
Akari Therapeutics' Institutional Ownership of 3.79% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Akari Therapeutics and its competitors. Akari Therapeutics's current Institutional Ownership is 3.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akari Therapeutics stock overvalued right now?
Akari Therapeutics (AKTX) has a current Institutional Ownership of 3.79%. The current Institutional Ownership is 3.79%. Akari Therapeutics' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Akari Therapeutics (AKTX), the current Institutional Ownership is 3.79% as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Akari Therapeutics Business Description

Address 401 East Jackson Street, Suite 3300, Tampa, FL, USA, 33602
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
32GF Score

Get the complete analysis for AKTX

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.99
Price